Is Atai Beckley N.V. (ATAI) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.0% / 30% | 5.1% / 30% | 0.1% / 30% | 252.6% / 5% | ✗ NOT HALAL |
| DJIM | 2.0% / 33% | 5.1% / 33% | 0.1% / 33% | 252.6% / 5% | ✗ NOT HALAL |
| MSCI | 15.5% / 33% | 39.1% / 33% | 0.8% / 33% | 252.6% / 5% | ✗ NOT HALAL |
| S&P | 2.0% / 33% | 5.1% / 33% | 0.1% / 33% | 252.6% / 5% | ✗ NOT HALAL |
| FTSE | 15.5% / 33% | 39.1% / 33% | 0.8% / 50% | 252.6% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -3588.1% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -390.0% | |
| Return on Assets (ROA) | -30.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$82M |
| Free Cash Flow | -$83M |
| Total Debt | $25M |
| Debt-to-Equity | 2.1 |
| Current Ratio | 11.7 |
| Total Assets | $159M |
Price & Trading
| Last Close | $3.54 |
| 50-Day MA | $3.76 |
| 200-Day MA | $4.07 |
| Avg Volume | 4.6M |
| Beta | 1.6 |
|
52-Week Range
$1.15
| |
About Atai Beckley N.V. (ATAI)
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Atai Beckley N.V. (ATAI) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Atai Beckley N.V. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Atai Beckley N.V.'s debt ratio?
Atai Beckley N.V.'s debt ratio is 2.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 15.5%.
What are Atai Beckley N.V.'s key financial metrics?
Atai Beckley N.V. has a market capitalization of $1.2B, and revenue of $308,000. Return on equity stands at -390.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.